Mitochon Pharmaceuticals » Logo
Mitochon Pipeline
Mitochon Pipeline
Preclinical Efficacy
IND Enabling Activities
Phase I
Phase II

Traumatic Brain Injury (TBI)

Significant Health Issue in US Both Military and Civilian.
No FDA nor DOD approved therapeutics.
NIH grant award for $3.2MM to develop MP-201.
Cofunded BrightFocus/MTEC Grant for MP-201 IND enabling $500,000.
TBI causes impaired mitochondrial respiration (low oxygen consumption) and high ROS production, calcium overload.
TBI Model: cortical impact.
Treatment: 80 mg/kg MP201 (Mice) 2-hours post injury for 2 weeks.
Our Data Shows:
Increased cortical sparing (p <0.01; 38% lesion spared).
Improved cognitive outcome (p<0.05).

MP201 Significantly Protects Cortex From Blunt Trauma.

Hubbard, W.B., et al., Mitochondrial uncoupling prodrug improves tissue sparing, cognitive outcome, and mitochondrial bioenergetics after traumatic brain injury in male mice. J Neurosci Res, 2018.

MP201 Leads To Cognitive Improvement Post TBI

Contact Us

We would like to hear from you if you want information on our endeavors or wish to learn more about our research efforts.